Authors
Latest:
How Pharmas, Payers, and Providers Can Meet the ‘Triple Aim’Today’s model requires a fourth partner-the systems integrator
Latest:
Rebooting Life Sciences with DigitalMastering digital business strategies and tactics will enable life sciences companies to supercharge innovation and speed therapy discovery, patient centric-practices and improved health outcomes, writes Bhaskar Sambasivan.
Latest:
e-Data and the Biopharmaceutical Supply ChainMilliporeSigma’s Stephen Wing, head of Analytical and Logistical Services, discusses the ways in which digital transformation and data transparency dramatically enhance supply chains, and how manufacturers are using the company’s eMERGE™ platform to improve overall efficiencies.
Latest:
Are We Slaves to Predictability?The status quo pharma marketing model is still relied upon by the big brands, not because the results are amazing, but because they are predictable. It's time to challenge convention, says James Talerico.
Latest:
When HIPAA Doesn’t ApplyOutlining the common data transactions between life sciences companies and the HIPAA-regulated stakeholders they deal with daily-and steps pharma can take to secure and protect its own data.
Latest:
When HIPAA Doesn’t ApplyOutlining the common data transactions between life sciences companies and the HIPAA-regulated stakeholders they deal with daily-and steps pharma can take to secure and protect its own data.
Latest:
How Can We Be Healthcare Leaders Right Now?Brenda Gleason discusses the current health policy landscape and how future pharmacists can be healthcare leaders during a lecture at University of North Carolina Eshelman School of Pharmacy.
Latest:
Resilience in a Sea of Change: Ed Gudaitis, GM – Canada, AllerganEd Gudaitis Allergan VP and Country Manager, Canada, explains how embracing disruption is his secret to success.
Latest:
Developing Drugs for Rare Diseases: Insights for Pharma ExecsThis article explores the difficult nature of developing drugs for rare diseases and discusses what a pharmaceutical executive can actively do to help increase success.
Latest:
Medical Marijuana: A Challenge to Traditional Pain Relief?Medical use of marijuana for a broad range of conditions is expanding rapidly in the US, but the future for this market is still uncertain, writes Harriet Kozak.
Latest:
Engaging in Risk-Sharing Agreements with ProvidersBefore entering into risk-sharing agreements, manufacturers must understand the challenges and implications, writes Kimberly E. White.
Latest:
Global Real World Data Tour: 2024 Key InsightsWebinar Date/Time: Wednesday, October 9th, 2024 at 11am EDT | 8am PDT | 4pm BST | 5pm CEST
Latest:
Job Hunter Meet Headhunter (aka Executive Recruiter)John Sattler offers some tips on engaging executive and professional recruiters.
Latest:
How HEOR Can Claim the SpotlightIf HEOR teams don’t clearly and concisely define themselves, their discipline, and their mission, they risk failure and irrelevance. A thoughtful communications program aimed at colleagues will win them due recognition of the value they bring, a say in key business decisions, and ongoing relevance.
Latest:
Pragmatic Therapy: Balancing Innovation, Cost, and Careis spectacular science enough to guarantee success for new medicines?
Latest:
Multidisciplinary Care Teams: Challenge or Opportunity?Abigail Bernardi explains how a better understanding of connections among practitioners on care teams helps sales reps build relationships while benefitting a company’s marketing efforts.
Latest:
QIDP: An Insufficient Policy?The GAIN Act creates a process for the Qualified Infectious Disease Product (QIDP) designation, which provides a range of incentives for developing antimicrobial therapies for combating resistant organisms. But while the program has been successful in driving innovation, commercial viability remains a question.
Latest:
Taking Command of Strategy ExecutionMark Bouch, Stephen Bungay, and David Roblin outline how the technique of "mission command", a military approach to setting direction and executing strategy in the pharmaceutical industry, has developed over the last ten years.
Latest:
The Power of MSL AuthenticityPaul Meade and Mark Schoeman describe the determining factor driving effective relationships between medical science liaisons and key opinion leaders.
Latest:
US Healthcare Could Be the Booster Shot That “Healthy China” NeedsThe Chinese government's “Healthy China” plan presents an unprecedented opportunity for the US healthcare industry and its investors, writes Steven Shill.
Latest:
Lessons Learned from the Multichannel ShakeoutInnovation by itself won't solve the complex multichannel challenges pharmas face.
Latest:
Access and Reimbursement for Adoptive T-Cell Transfer DrugsGroundbreaking treatment approaches call for innovative commercialization strategies.
Latest:
Access and Reimbursement for Adoptive T-Cell Transfer DrugsGroundbreaking treatment approaches call for innovative commercialization strategies.
Latest:
Access and Reimbursement for Adoptive T-Cell Transfer DrugsGroundbreaking treatment approaches call for innovative commercialization strategies.
Latest:
Access and Reimbursement for Adoptive T-Cell Transfer DrugsGroundbreaking treatment approaches call for innovative commercialization strategies.
Latest:
Dermatology Biologics: Overcoming Challenges to Fulfill Therapeutic PotentialDarcee Strube offers an overview of the key issues and progress made in dermatology biologics.
Latest:
America’s Opioid Crisis: Potential Increased Regulation of MarketingWith over 70 companies manufacturing immediate-release opioids in the United States, federal regulators may look to limit, or at least impose greater control over, marketing as a strategy to reduce the prescription, and more specifically, the improper and/or over-prescription of opioids.
